On-chip micro-flow polystyrene bead-based immunoassay for quantitative detection of tacrolimus (FK506).
暂无分享,去创建一个
Tatsuro Endo | Yuzuru Takamura | Eiichi Tamiya | Naoki Nagatani | Shouhei Yamamura | E. Tamiya | Y. Takamura | N. Nagatani | T. Endo | Yoshihiro Murakami | Y. Murakami | S. Yamamura
[1] C. Staatz,et al. Comparison of an ELISA and an LC/MS/MS Method for Measuring Tacrolimus Concentrations and Making Dosage Decisions in Transplant Recipients , 2002, Therapeutic drug monitoring.
[2] P. Kandela. South Africa: medical care of detainees. , 1985, Lancet.
[3] M. Christiaans,et al. Dosing and management guidelines for tacrolimus in renal transplant patients. , 1999, Transplantation proceedings.
[4] H. Schiebel,et al. Simplified High‐Performance Liquid Chromatography‐Mass Spectrometry Assay for Measurement of Tacrolimus and Its Metabolites and Cross‐Validation with Microparticle Enzyme Immunoassay , 1995, Therapeutic drug monitoring.
[5] D. Faulds,et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. , 1993, Drugs.
[6] F. Berthoux,et al. Comparison of ELISA method versus MEIA method for daily practice in the therapeutic monitoring of tacrolimus. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] G. Klintmalm. FK 506: an update. , 1994, Clinical transplantation.
[8] T. Starzl,et al. FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION , 1989, The Lancet.
[9] P. Wallemacq,et al. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. , 1995, Clinical chemistry.
[10] A. Alak,et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. , 1997, Journal of pharmaceutical and biomedical analysis.
[11] T. Starzl,et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. , 1991, Transplantation proceedings.
[12] P. Taylor,et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. , 1998, Clinical chemistry.
[13] N. Undre,et al. Pharmacokinetics of tacrolimus: clinically relevant aspects. , 1999, Transplantation proceedings.
[14] P. Wong,et al. A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents. , 1996, Therapeutic drug monitoring.
[15] S. Nishimura,et al. Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] W. Jusko. Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug Monitoring , 1995, Therapeutic drug monitoring.
[17] Mangan Kf. Immunologic control of hemopoiesis: implications for quality of the graft after allogeneic bone marrow transplantation. , 1987 .
[18] D. Stephen,et al. Evaluation of the Dade Behring Syva® EMIT 2000 tacrolimus assay on the Bayer Advia 1650 , 2003, Annals of clinical biochemistry.
[19] M. Kobayashi,et al. A whole blood FK 506 assay for the IMx analyzer. , 1991, Transplantation proceedings.